CAGE Bio begins phase 2b clinical trial for CGB-500, a breakthrough topical JAK inhibitor for moderate to severe atopic dermatitis: San Carlos, California Saturday, January 11, 20 ...
Analysts at Zacks Research upped their FY2024 EPS estimates for Nektar Therapeutics in a report issued on Monday, January 6th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback